Sterling Pharma Solutions, a global contract development and manufacturing organization, and Soligenix, a late-stage biopharmaceutical company focused on developing products to treat rare diseases, entered an agreement for Sterling to manufacture a GMP-quality synthetic hypericin developed by Soligenix, for its oncology drug, HyBryte, for clinical trials.   Process development of the synthetic hypericin is currently underway at Sterling’s Germantown, WI facility ahead of clinical-scale GMP man...